Although I, too, think RVNC frosted the data from the BELMONT study—see #msg-118159012—the MOX Reports blog is deeply flawed for using Dysport (a clearly inferior product to Botox) as a valuation comparator for RNVC.
All told, I think RVNC’s RT002 has the potential to be a solid product and to garner respectable market share, but it’s not the “game changer” that RVNC makes it out to be.
I would consider going long RVNC at a lower entry point (#msg-118173728), but I do not consider it a candidate for shorting.
Market Data 
Markets 
AI
